FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
May 14, 2015
Consolidated Resources will Better Serve HeartCheck™, GEMS™ WIN and New Product Sales.
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today confirmed it has received new regulatory certification from the Canadian Medical Devices Conformity Assessment System (CMDCAS) specifically for its Toronto facilities. Global Business/Product Development, Regulatory, Quality, Development, Service and Sales Systems will now be based out of the Company's Toronto location.
Securing ISO audit and EC-Certification will permit more efficient and cost effective marketing and sales support for CardioComm Solutions' flagship products, the HeartCheck™ ECG devices and GEMS™ WIN (Global ECG Management Solution for Windows 7). With operations, sales and product development in one location, the Company will also be positioned to respond optimally to growing GEMS™ WIN sales and installation requests and GEMS™ WIN custom software engineering projects.
With product engineering, testing and quality auditing occurring at the same location, the Company's capacity for meeting expanding applications for use of the HeartCheck™ devices, GEMS™ Home and the announced plans for a wireless HeartCheck™ device for Smartphone connectivity will also be strengthened.
The Company also confirms it will now close its Victoria location, which will provide operational and maintenance cost savings. A review of the CardioComm Solutions' 2014 financial statements show a progressive reduction in overhead expenses, which will be further reduced with all corporate activities amalgamated into one location.
CardioComm Solutions is registered under Health Canada's Therapeutic Products Programme (TPP) according to ISO 13485:2003 and CMDCAS as well as MDD regulations, for the Manufacturing and Distribution of Health Management Software Systems and Distribution of Health Monitoring Devices. The mission of the TPP, and the purpose of the audit, is to ensure that drugs, medical devices, and other therapeutic products available in Canada are safe, effective and are of high quality.
CardioComm Solutions has for several years received such clearances through its Victoria, BC, location which audit: Management Reviews, Procedures; Corrective Action Loops, Production and Process Controls; Customer Related Processes; Implementation of Applicable Canadian Medical Devices Regulations - Part 1 Requirements; Implementation of Regulatory Requirements of the Directive 93/42/EEC; and Document Control Processes. The audit concluded that CardioComm Solutions' Toronto location has fulfilled the requirements of all applicable ISO 13485:2003 standards as well as Canadian regulatory requirements.
More information about the Company and its products and services can be found at www.cardiocommsolutions.com.
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of